Brown, Lisle/Cummings’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.97M Sell
3,308
-45
-1% -$46K 0.89% 28
2026
Q1
$3.08M Buy
3,353
+33
+1% +$33.5K 0.77% 36
2025
Q4
$3.57M Hold
3,320
0.88% 30
2025
Q3
$2.53M Sell
3,320
-65
-2% -$48.4K 0.65% 42
2025
Q2
$2.64M Sell
3,385
-39
-1% -$30.3K 0.7% 39
2025
Q1
$2.83M Buy
3,424
+146
+4% +$121K 0.82% 35
2024
Q4
$2.53M Buy
3,278
+1,234
+60% +$1.02M 0.76% 36
2024
Q3
$1.81M Hold
2,044
0.55% 47
2024
Q2
$1.85M Sell
2,044
-25
-1% -$20K 0.6% 44
2024
Q1
$1.61M Hold
2,069
0.55% 46
2023
Q4
$1.21M Sell
2,069
-50
-2% -$29.2K 0.45% 55
2023
Q3
$1.14M Buy
2,119
+50
+2% +$25.8K 0.52% 48
2023
Q2
$970K Buy
2,069
+86
+4% +$36.1K 0.43% 56
2023
Q1
$681K Sell
1,983
-50
-2% -$16.9K 0.35% 71
2022
Q4
$744K Buy
2,033
+200
+11% +$70.9K 0.4% 59
2022
Q3
$593K Hold
1,833
0.35% 75
2022
Q2
$594K Sell
1,833
-100
-5% -$30K 0.33% 77
2022
Q1
$554K Hold
1,933
0.27% 87
2021
Q4
$534K Buy
+1,933
New +$490K 0.27% 91

Other funds holding LLY

Brown, Lisle/Cummings's LLY Position: Q2 2026 in Review

Brown, Lisle/Cummings reduced its Eli Lilly (LLY) stake by 1.3% in Q2 2026, selling an estimated $46K and leaving 3,308 shares worth $3.97M. The position accounts for 0.89% of the portfolio, ranked #28.

Brown, Lisle/Cummings first reported a position in LLY in Q4 2021 and has held it in 19 quarters since. 4,624 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Brown, Lisle/Cummings held 3,308 shares of Eli Lilly worth $3.97M as of Q2 2026.
  • Brown, Lisle/Cummings sold 45 Eli Lilly shares in Q2 2026, an estimated $46K.
  • Eli Lilly made up 0.89% of Brown, Lisle/Cummings's portfolio in Q2 2026, its #28 holding.
  • Brown, Lisle/Cummings first reported a position in Eli Lilly in Q4 2021 and has held it in 19 quarters since.
  • 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q2 2026, filed 2 Sep 2026.